Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $75

Benzinga Newsdesk www.benzinga.com Positive 80.5%

Neg 0% Neu 0% Pos 80.5%

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $60 to $75.